A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) is a phase 3 interventional study registered as NCT03592472, led by Xynomic Pharmaceuticals, and recruiting on the registry. Official title: A Randomised, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV). Planned enrolment is 413 participants (estimated). The study started in 2018-07-17 and primary completion is expected in 2026-12-30. No results have been posted on ClinicalTrials.gov.